Financial Contrast: Redhill Biopharma (RDHL) vs. Its Peers

Redhill Biopharma (NASDAQ: RDHL) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Redhill Biopharma to similar businesses based on the strength of its profitability, valuation, risk, earnings, institutional ownership, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of current ratings for Redhill Biopharma and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Redhill Biopharma 0 0 4 0 3.00
Redhill Biopharma Competitors 846 3196 11591 230 2.71

Redhill Biopharma currently has a consensus price target of $25.00, suggesting a potential upside of 421.92%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 46.49%. Given Redhill Biopharma’s stronger consensus rating and higher probable upside, analysts plainly believe Redhill Biopharma is more favorable than its peers.

Volatility & Risk

Redhill Biopharma has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500. Comparatively, Redhill Biopharma’s peers have a beta of 6.22, indicating that their average share price is 522% more volatile than the S&P 500.

Valuation & Earnings

This table compares Redhill Biopharma and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Redhill Biopharma $100,000.00 -$29.37 million -1.77
Redhill Biopharma Competitors $284.28 million $34.29 million 134.95

Redhill Biopharma’s peers have higher revenue and earnings than Redhill Biopharma. Redhill Biopharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


This table compares Redhill Biopharma and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Redhill Biopharma N/A -85.09% -67.92%
Redhill Biopharma Competitors -5,306.52% -432.90% -39.18%

Insider & Institutional Ownership

8.5% of Redhill Biopharma shares are owned by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 16.6% of shares of all “Bio Therapeutic Drugs” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.


Redhill Biopharma peers beat Redhill Biopharma on 7 of the 12 factors compared.

Redhill Biopharma Company Profile

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103).

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply